New drug cocktail shows promise against tough kidney cancer
NCT ID NCT01038778
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 25 times
Summary
This study tests a combination of two drugs—entinostat and aldesleukin—for people with kidney cancer that has spread. The goal is to find the safest dose and see if the combo can shrink tumors. About 47 adults with clear cell kidney cancer are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
Conditions
Explore the condition pages connected to this study.